{"schema_version":"secwatch.filing_event.v1","accession":"0001613103-24-000006","form_type":"8-K","ticker":"MDT","cik":"0001613103","company_name":"Medtronic plc","filed_at":"2024-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.808673+00:00","generated_at":"2026-06-05T23:07:45.649504+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Medtronic Q3 FY2024: Revenue $8.1B, GAAP EPS $0.99, raises FY24 guidance; exits ventilator business","bullets":["Q3 revenue $8.089B, up 4.7% reported and 4.6% organic; GAAP EPS $0.99, non-GAAP EPS $1.30.","Raises FY24 organic revenue growth guidance to 4.75%-5% and non-GAAP EPS to $5.19-$5.21.","Exiting ventilator product line; combining PMRI into Acute Care & Monitoring unit.","EVP Robert J. White to leave April 26, 2024 due to organizational changes.","Diabetes revenue $640M, up 12.3%, U.S. returns to growth; CE Mark for MiniMed 780G with Simplera Sync."],"urls":{"canonical":"https://secwatch.observer/filing/0001613103-24-000006","json":"https://secwatch.observer/filing/0001613103-24-000006.json","markdown":"https://secwatch.observer/filing/0001613103-24-000006.md","text":"https://secwatch.observer/filing/0001613103-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000006/0001613103-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000006/mdt-20240213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T23:07:45.649504+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab95cc1815461e2faa5f58b40ce632e78a926f36","claim":"Medtronic plc reported third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024 results: revenue $8.1 billion, net income $1.322 billion, EPS $0.99. Guidance raised.","evidence_excerpt":"Revenue of $8.1 billion increased 4.7% as reported and 4.6% organic • GAAP diluted earnings per share (EPS) of $0.99; non-GAAP diluted EPS of $1.30 • Raises FY24 organic revenue growth and EPS guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000006/0001613103-24-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024"},{"label":"Revenue","value":"$8.1 billion"},{"label":"Net income","value":"$1.322 billion"},{"label":"EPS","value":"$0.99"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d57ec8fd11","claim":"Robert J. White departed as Executive Vice President and President of Medtronic’s Medical Surgical Portfolio at Medtronic plc.","evidence_excerpt":"Mr. White will leave the Company effective April 26, 2024, and because Mr. White’s separation from Medtronic constitutes a termination without cause, Mr. White will receive severance payments and benefits consistent with Medtronic’s severance practices for executive officers, as described in Medtronic’s 2023 Proxy Statement filed with the Securities and Exchange Commission on August 11, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613103/000161310324000006/0001613103-24-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"leave"},{"label":"Role","value":"Executive Vice President and President of Medtronic’s Medical Surgical Portfolio"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}